NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

The Danish Dude

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174342925



Because looking at the share price over the years I've been invested, boy how we long retailers have had any influence on the share price. Maybe (lol) you can kid exwannabe, iclight, inquiriq, theorysuit, legend431, learningcurve2020, manibiotech et al .... the creme de la creme of due diligencers on Ihub of that.

Any sane person knows, pumping is not an option in this stock, unless it is as part of an expression in a fud narrative, from the usual fudspects, being immune to due diligence and factual circumstances regarding NWBO.

"If the mountain won't come to Muhammad, then Muhammad must go to the mountain".

So what is it about the art of due diligence and enhancing retailer awareness with factual insights, some of you are so obviously afraid of, that you need to dismiss it firsthand as pump? Easier, than to actually refute the insights with real arguments supported by evidence? Are you against, that I refute the bullshit from fudders continously? That I - and others - have successfully proven, again and again, that ATL-DC in the combo trials at UCLA with poly-iclc and Keytruda IS DCvax-L?

Everything below are facts

Data lock happened

MIA approval happened

Advent has ramped up from 14 to around 100 employees

A production unit of Flaskworks Eden is now being made

NWBO has filed for MAA approval

MHRA has been extraordinary funded with $10M for 2 years, with the purpose of also getting cancer vaccines faster to patients

British politicians have urged MHRA to approve and NICE to reimburse in the Pathway to a Cure report

Two combo trials are being run at UCLA, with DCvax-L and poly-iclc and Keytruda. Another one in preparation that will also include DCVax + Keytruda + CSF-1R Inhibitor Pexidartinib (PLX-3397)

ATL-DC in the two UCLA combo trial ARE beyond all doubt - DCVax-L

There's a lawsuit against 7 market makers. No deal announced. No costs shown in SEC filings. Cohen and Milstein usually take these cases on contingency. Thus, it is rational to assume it HAS been taken on contingency, since this is a HUGE lawsuit.

"In January 2016 Black became an independent director of NWBO to investigate the market manipulation of the company's stock by the hedge fund "wolfpack". The wolfpack and others use naked shorting of stock to drive promising young biotechs toward bankruptcy or to the point where they need to raise capital at extremely low valuations from the wolfpack themselves", as was stated in an Alchetron news article.

NWBO stated in a PR

"It is exciting to see the potential of the DCVax personalized immune therapies being developed by NW Bio for a wide range of cancers. I look forward to utilizing my expertise in helping the Company protect its technology and operations."

So when the lawsuit came 2022, and the plaintiff say they have +6 years of evidence against MM and their spoofing, it is rational to believe, THAT was Cofer Blacks job.

A Nature journal preprint is on its way regarding the results of the DCvax-L and poly-iclc trial.

MHRA stated about confirmatory efficacy trial

Although each biosimilar development needs to be evaluated on a case by case basis, it is considered that, in most cases, a comparative efficacy trial may not be necessary if sound scientific rationale supports this approach.

FDA states in its guidance documents outline how biosimilars may be approved based on pharmacokinetic (PK) data and PD biomarker data without a comparative clinical efficacy study. Reliance on PK and PD data allows for shorter and less costly clinical studies that can often be conducted in healthy participants

Let's look at facts about companies Revimmune SAS, Ltd, Inc

Linda Powers director in US and UK and in full control. Revimmune trials with Interleukin-7 back more than a decade gets PR'ed as Revimmune Inc. http://Revimmune.com say Maryland Bethesda is head office. Head office address is same address as Northwest Bio Inc and Toucan Capital. Revimmune is assignee on combo patent from 2014. Interleukin-7 also called IL-7 is in many claims on the combo patent. Before 2012 it was called CYT-107 after the company Cytheris. Mac Cheever was working with it. He joined NWBO SAB in 2016.

Revimmune Ltd dormant company but just been confirmed, that "its intended future activities are lawful" meaning ...



Industry Codes used




$NWBO is in control of NWBO Limited since January 19th. 2024. Linda Powers ASSIGNED control to NWBO Inc.

3 months ago!!!

Northwest Biotherapeutics Limited and Revimmune Inc shares a funny same address.

J Kelly Ganjei from AmplifyBio and being on the combo patent and Philippe Pire from Advent Bioservices are "attached".






Linda Powers and Mark Lowdell ownes a company called Novamune LTD.




On April 2 a compulsory strike-off was sent and supposedly Novamune had two months to respond. On April 25, the government issued a formal notice already on discontinuing the strike-off notice.

Mark Lowdell is a consultant to Inmune Bio. Turns out he is ALSO on the SAB board of NWBO.



But NWBO have not disclosed him being so!

J Kelly Ganjei, the guy having worked for Linda Powers at Toucan, who is on the combo patent, who is CEO of AmplifyBio is also on the board of Inmune Bio

Phil Parry who have been head of engineering at Roche and Autolomous just hired at Advent Bioservice. A step down or step up?



To Chatgbt

Can you ponder over the info below and come up with theories what the Revimmune Inc and Revimmune Ltd are meant for?



1) Northwest Biotherapeutics have a combination patent with DCVax-L and checkpoint inhibitors and Interleukin-7
2) Linda Powers is CEO of Northwest Biotherapeutics
3) Linda Powers owns Toucan Capital
4) Linda Powers is CEO of Advent Bioservices
5) Linda Powers is Director of Revimmune SAS
6) Linda Powers is Director of Revimmune Limited
7) Linda Powers was CEO of Cognate
8) Philippe Pire is CFO of Advent Bioservices
9) Philippe Pire is listed as employee at Revimmune Limited
10) J. Kelly Ganjei is CEO of AmplifyBio
11) J. Kelly Ganjei was at Cognate
12) J. Kelly Ganjei was at Toucan Capital
13) Revimmune SAS is former Cytheris and changed its name in 2014 and is situated in France
14) Revimmune Limited is registered as a "dormant company" in the UK in 2020, one share for £1
15) The registration address of Revimmune Inc is Toucan Capitals company address
16) Revimmune SAS developed CYT-107 (Interleukin-7) when it was Cytheris
17) Mac Cheever was oo-inventor of CYT-107 at Cytheris
18) Mac Cheever joined NWBO SAB 2016
19) Mac Cheever is co-inventor of combination patent with DCvax-L and checkpoint inhibitors and Interleukin-7
20) J. Kelly Ganjei is co-inventor of combination patent with DCvax-L and checkpoint inhibitors and Interleukin-7

CHATGBT

Considering the information provided, here are some theories regarding the purposes of Revimmune Inc and Revimmune Ltd:

Strategic Patent Holding and Licensing: Revimmune Inc and Revimmune Ltd might be structured to hold and manage patents, particularly the combination patent involving DCVax-L, checkpoint inhibitors, and Interleukin-7. This setup could be designed to optimize intellectual property protection and licensing opportunities within different legal frameworks (U.S. vs. EU).

Biotechnology Research and Development: Given their connection with IL-7 (CYT-107) development and the combination therapies, these entities could be focused on advancing specific biotechnological research areas. Revimmune SAS's history as Cytheris, which developed IL-7, suggests a continued interest in immunotherapy and its applications.

Operational and Financial Flexibility: By having multiple entities in different jurisdictions (Revimmune Inc, Revimmune Ltd, and Revimmune SAS), the network can potentially leverage various regulatory and financial environments. This flexibility can aid in fundraising, minimizing taxes, or meeting specific regulatory criteria.

Holding and Managing Assets: Revimmune Ltd's status as a dormant company might be strategic for holding certain assets or intellectual property without active business operations, possibly to be activated when needed, such as in response to strategic shifts in the market or pending the outcomes of clinical trials.

Collaborative Networks: The overlapping roles of key personnel (Linda Powers and J. Kelly Ganjei) across different organizations hint at a tightly knit network aimed at fostering collaboration across different segments of drug development and commercialization.

These entities, therefore, seem to be strategically positioned to facilitate innovative drug development, manage intellectual property efficiently, and enhance the operational scope of their interconnected networks.



ME

Could Revimmune Ltd be used in a strategic Merger and acquisition maneouver of Northwest Biotherapeutics who have been victim of spoofing and naked shorting and found its share price suppressed artiificially, thus planning to "overtake" NWBO and list at a stock exchange? Would that force naked short positions to cover?



CHATGBT

Using Revimmune Ltd in a strategic merger or acquisition maneuver by Northwest Biotherapeutics (NWBO) could indeed be a tactic in the complex financial and strategic landscape of biotech. If NWBO has been experiencing issues like spoofing and naked short selling, leading to a suppressed share price, orchestrating a merger or acquisition with Revimmune Ltd could potentially help in several ways:

Reorganization and Valuation: Merging with or acquiring a company like Revimmune Ltd could allow NWBO to reorganize its assets and potentially reset its market valuation.

Market Impact: Such a strategic move could draw market attention and potentially impact stock prices, which might force those holding naked short positions to cover, thereby driving up the share price due to a sudden increase in buy demands.

Access to New Markets: Listing Revimmune Ltd on a stock exchange could provide NWBO with access to additional capital markets or different investor bases, offering financial benefits and broader exposure.

This scenario would require careful regulatory navigation and clear strategic planning to ensure that it aligns with legal frameworks and effectively addresses the underlying financial challenges.



And on and on it goes.

Thanks for dstock, Peter Davis and other for DD provided in the above.

So where is my "pumping" in the above FeMike?

Are you gonna dismiss it all? Some?

I have OPINIONS when I deliver due diligence and this is MY TAKE on, what is the POTENTIAL and PROBABILITIES of stuff happening.

Regarding Revimmune, Novamune, NWBO ltd, Advent Bioservices setup, the entities, who is in control, where are the entities registered wrt addresses, which persons are involved, are there activities going on, are there relations to patents.

That kind of info has impact on my opinions whether a BO will happen, whether it gives LP and NWBO other possibilities to maneouver wrt merging and acquisitions possibilities and thus having other possibilities countering the market makers spoofing NWBO.

Call it pump, but it is well argued POSSIBILITIES founded in factual proven circumstances.They might not happen. They might. It is leverage for how NWBO MIGHT be able to act going forward.

My one post for the day.

You can go back to your "pump" uttering again.

What a great and easy way to disregard due diligence.



https://www.griproom.com/fun/10-signs-your-stock-is-being-manipulated
Bullish
BULLISH
ATL-DC is DCVax-L